Oncologydevelopments

Highlights from an interesting panel from yesterday led by Dr. Elez (Vall d’Hebron) and Dr. Spencer (NYU Langone). IO in solid organ transplant recipients, effect of time-of-day for combo immuno-chemotherapy in advanced NSCLC, ultra low-dose IO in solid tumors, and more. #ASCO25

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Great talk by Dr. Vanita Noronha from Tata Memorial Hospital discussing phase III results from the DELII study, comparing low-dose IO to chemotherapy for solid tumors in the 2nd line and beyond. An interesting option when full dose IO is inaccessible or unaffordable. #ASCO25

Exciting data presented this morning by Janice Mehnert, MD (@JaniceM10) from NYU Langone Perlmutter Cancer Center. Phase II results of sarilumab in combo with ipi/nivo/rela in advanced melanoma showed a 12.1% grade 3-5 irAE rate and a 63.6% response rate at 24 weeks. #Melanoma

Highlights from this morning’s skin cancers session #ASCO2025 Sarilumab in combo with ipi, nivo, rela in advanced melanoma. Dr. Mehnert, NYU Langone DYP688 in metastatic uveal melanoma. Dr. Carlino, MIA High fiber diet in melanoma patients receiving ICB. Dr. Qiu, MD Anderson

So much to see at #ASCO2025. Looking forward to an exciting several days in Chicago.